Environmental endocrine disruptors in cardio-oncology: emerging modifiers of cardiovascular vulnerability in patients with cancer
Abstract
Background: Cardio-oncology has traditionally focused on treatment-related cardiovascular toxicity and conventional cardiovascular risk factors. However, increasing evidence suggests that environmental exposures may contribute to both cancer development and cardiovascular disease through shared biological mechanisms. Endocrine-disrupting chemicals (EDCs) are ubiquitous environmental contaminants capable of interfering with hormonal signaling, metabolic homeostasis, vascular function, and inflammatory pathways. Despite growing evidence linking EDCs to cardiometabolic disorders and hormone-sensitive malignancies, their potential role within the cardio-oncology continuum remains largely unexplored.
Methods: This narrative review summarizes and critically discusses current experimental, translational, and epidemiological evidence regarding the potential contribution of environmental endocrine disruptors to cardiovascular risk and cancer biology. Particular attention is given to molecular pathways relevant to cancer therapy-related cardiovascular toxicity, breast cancer biology, adipose tissue dysfunction, and emerging exposomic determinants of long-term cardiovascular outcomes in patients with cancer.
Main body: Major classes of EDCs, including bisphenols, phthalates, per- and polyfluoroalkyl substances (PFAS), persistent organic pollutants (POPs), parabens, pesticides, and other environmental contaminants, are continuously encountered through food systems, plastics, consumer…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.